This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Regional enteritis and ulcerative colitis
  • /
  • Switching to biosimilars: current perspectives in ...

Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases.

Read time: 1 mins
Published:1st Oct 2019
Author: Edwards CJ, Hercogová J, Albrand H, Amiot A.
Availability: Free full text
Ref.:Expert Opin Biol Ther. 2019;19(10):1001-1014.

Introduction: The expiry of patents for biologics has led to the introduction of biosimilars for the treatment of immune-mediated inflammatory diseases (IMIDs). These treatment alternatives may allow earlier and wider access to appropriate therapy for patients without increasing the economic burden on health-care systems. Prescription of biosimilars to treatment-naïve patients is well accepted; however, additional considerations must be taken into account when switching clinically stable patients from reference products to biosimilars.

Area covered: We discuss the current considerations related to switching from reference products to biosimilars from a physician and patient perspective. We review the clinical data and real-life experience on switching patients with IMIDs, present the position of the relevant medical societies, and discuss the importance of patient–physician communication and need for shared decision-making.

Expert opinion: The introduction of biosimilars provides an opportunity to expand access to treatment for patients with IMIDs across Europe and support the financial sustainability of health-care systems. We anticipate that as the real-world evidence base grows, confirming the results of clinical trials, there will be a corresponding increase in physician and patient acceptance, not only to initiating treatment with a biosimilar, but also to switching medication from a reference product to a biosimilar.


Read abstract on library site

Access full article